Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma ("HCC") study demonstrating: Survival benefit maintained across key subpopulations a six-month improvement over control arm in median survival a strong 0.65 hazard ratio, maintained since 0.59 observed 10 months earlier Advancing amezalpat towards a pivotal Phase 3 trial in first-line HCC Planning to move TPST-1495 into a Phase 2 in FAP BRISBANE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tempest T ...